DIVIS LABORATORIES
|
DIVIS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 96.91 | 82.68 | 60.38 | 68.83 | 111.53 |
| CEPS(Rs) | 114.38 | 97.85 | 74.64 | 81.77 | 123.26 |
| DPS(Rs) | 30.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Book NAV/Share(Rs) | 632.49 | 564.87 | 512.11 | 481.77 | 441.82 |
| Tax Rate(%) | 24.20 | 24.86 | 26.03 | 23.01 | 19.63 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 32.74 | 31.86 | 27.96 | 30.30 | 43.18 |
| EBIT Margin(%) | 32.46 | 31.34 | 27.46 | 30.32 | 41.00 |
| Pre Tax Margin(%) | 32.23 | 31.31 | 27.41 | 30.30 | 40.98 |
| PAT Margin (%) | 24.43 | 23.53 | 20.28 | 23.33 | 32.94 |
| Cash Profit Margin (%) | 28.83 | 27.84 | 25.07 | 27.71 | 36.40 |
| Performance Ratios | |||||
| ROA(%) | 13.31 | 13.02 | 10.39 | 12.37 | 22.77 |
| ROE(%) | 16.19 | 15.35 | 12.15 | 14.89 | 28.16 |
| ROCE(%) | 21.51 | 20.45 | 16.46 | 19.36 | 35.06 |
| Asset Turnover(x) | 0.54 | 0.55 | 0.51 | 0.53 | 0.69 |
| Sales/Fixed Asset(x) | 1.22 | 1.27 | 1.20 | 1.30 | 1.74 |
| Working Capital/Sales(x) | 1.16 | 1.08 | 0.94 | 0.95 | 1.26 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.82 | 0.79 | 0.83 | 0.77 | 0.57 |
| Receivable days | 99.21 | 95.77 | 91.33 | 98.42 | 83.26 |
| Inventory Days | 124.81 | 125.81 | 143.02 | 136.04 | 100.99 |
| Payable days | 94.57 | 84.95 | 92.50 | 93.12 | 95.88 |
| Valuation Parameters | |||||
| PER(x) | 61.36 | 69.83 | 56.92 | 41.05 | 39.49 |
| PCE(x) | 51.99 | 59.00 | 46.04 | 34.56 | 35.73 |
| Price/Book(x) | 9.40 | 10.22 | 6.71 | 5.87 | 9.97 |
| Yield(%) | 0.50 | 0.52 | 0.87 | 1.06 | 0.68 |
| EV/Net Sales(x) | 14.60 | 15.95 | 11.10 | 9.10 | 12.73 |
| EV/Core EBITDA(x) | 39.04 | 44.95 | 34.22 | 26.04 | 28.54 |
| EV/EBIT(x) | 45.18 | 51.14 | 40.19 | 29.81 | 30.95 |
| EV/CE(x) | 9.20 | 9.97 | 6.42 | 5.54 | 7.80 |
| M Cap / Sales | 14.92 | 16.34 | 11.61 | 9.64 | 13.05 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.82 | 19.31 | 1.00 | -13.31 | 28.56 |
| Core EBITDA Growth(%) | 18.91 | 30.49 | -6.23 | -32.10 | 36.71 |
| EBIT Growth(%) | 16.89 | 34.70 | -8.60 | -35.67 | 38.13 |
| PAT Growth(%) | 17.21 | 36.94 | -12.28 | -38.39 | 49.19 |
| EPS Growth(%) | 17.21 | 36.94 | -12.28 | -38.28 | 49.19 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 4.12 | 4.84 | 5.78 | 6.34 | 3.92 |
| Quick Ratio(x) | 2.76 | 3.40 | 3.97 | 4.39 | 2.76 |
| Interest Cover(x) | 142.17 | 973.00 | 541.75 | 1,185.50 | 1,842.75 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹246,766.3 Cr | -3.3% | 1.4% | 57.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹434,280.0 Cr | -2.4% | -6.2% | 11.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,129.0 Cr | -4.5% | -4% | 35.9% | Stock Analytics | |
| CIPLA | ₹108,808.0 Cr | -3.6% | -5% | -10.6% | Stock Analytics | |
| MANKIND PHARMA | ₹104,376.0 Cr | 2.1% | 7.1% | -0.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,170.0 Cr | -0.2% | 2.5% | -3% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | -3.3% |
1.4% |
57.4% |
| SENSEX | -2.3% |
-6.6% |
-12% |
You may also like the below Video Courses
